Belumosudil

Last updated

Belumosudil
Belumosudil - KD025.svg
Clinical data
Trade names Rezurock, Rholistiq
Other namesKD025, SLx-2119
License data
Pregnancy
category
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Identifiers
  • 2-[3-[4-(1H-Indazol-5-ylamino)quinazolin-2-yl]phenoxy]-N-propan-2-ylacetamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C26H24N6O2
Molar mass 452.518 g·mol−1
3D model (JSmol)
  • CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5
  • InChI=InChI=1S/C26H24N6O2/c1-16(2)28-24(33)15-34-20-7-5-6-17(13-20)25-30-23-9-4-3-8-21(23)26(31-25)29-19-10-11-22-18(12-19)14-27-32-22/h3-14,16H,15H2,1-2H3,(H,27,32)(H,28,33)(H,29,30,31) Yes check.svgY
  • Key:GKHIVNAUVKXIIY-UHFFFAOYSA-N Yes check.svgY

Belumosudil, sold under the brand name Rezurock among others, is a medication used for the treatment of chronic graft versus host disease (cGvHD). [1] [5] [6] It is in the class of drugs known as serine/threonine kinase inhibitors. [6] Specifically, it is an inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II). [7] ROCK2-mediated signaling pathways are major players in pro- and anti-inflammatory immune cell responses. A study in cultured human cells demonstrated that the drug also has effects on oxidative phosphorylation, WNT signaling, angiogenesis, and KRAS signaling. [8]

Contents

The most common side effects include infection, tiredness or weakness, nausea, diarrhea, shortness of breath, cough, swelling, bleeding, stomach (abdominal) pain, muscle or bone pain, headache, and high blood pressure. [9]

Belumosudil was approved for medical use in the United States in July 2021. [5] [6] The US Food and Drug Administration considers it to be a first-in-class medication. [10]

Medical uses

Belumosudil is indicated for the treatment of people aged twelve years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy. [5] [6]

Chronic graft-versus-host disease is a complication that can occur after stem cell or bone marrow transplantation in which the transplanted donor cells attack the transplant recipient's body. [9]

History

Originally developed by Surface Logix, Inc, [7] belumosudil was later acquired by Kadmon Corporation. By July 2020, the drug completed Phase II clinical studies for cGvHD, IPF, and psoriasis. [11]

Chronic graft-versus-host disease is a complication that can follow allogeneic stem cell or hematopoietic stem cell transplantation where the transplanted cells (graft) attack healthy cells (host). This causes inflammation and fibrosis in multiple tissues. Two cytokines controlled by the ROCK2 signaling pathway, IL-17 and IL-21, have a major role in the chronic graft-versus-host disease response. In a 2016 report using both mouse models and a limited human clinical trial ROCK2 inhibition with belumosudil targeted both the immunologic and fibrotic components of chronic graft-versus-host disease and reversed the symptoms of the disease. [12]

In October 2017, belumosudil was granted orphan drug status in the United States for treatment of people with chronic graft-versus-host disease. [13]

Efficacy of belumosudil was evaluated in clinical trial NCT03640481, [14] a randomized, open-label, multicenter dose-ranging trial that included 65 patients with chronic graft-versus-host disease who were treated with belumosudil 200 mg taken orally once daily. [6] [9] A total of eighty-three (83) participants were evaluated for safety; therefore, the number of participants representing efficacy findings may differ from the number of participants representing safety findings due to different pools of study participants analyzed for efficacy and safety. [9] The trial was conducted at 28 sites in the United States. [9]

In July 2021, the US Food and Drug Administration (FDA) approved belumosudil for people aged twelve years of age and older with chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy. [6] [10]

Society and culture

In October 2025, the European Medicines Agency recommended the refusal of the marketing authorization for Rezurock, a medicine intended for the treatment of chronic graft-versus-host disease (a condition in which donor cells attack the body's organs) after a stem-cell transplant. [15]

References

  1. 1 2 3 "Rholistiq". Therapeutic Goods Administration (TGA). 26 November 2021. Archived from the original on 28 December 2021. Retrieved 28 December 2021.
  2. 1 2 "AusPAR: Belumosudil". Therapeutic Goods Administration (TGA). 10 May 2022. Archived from the original on 10 May 2022. Retrieved 10 May 2022.
  3. ↑ "Archived copy" (PDF). Archived (PDF) from the original on 29 June 2022. Retrieved 29 June 2022.{{cite web}}: CS1 maint: archived copy as title (link)
  4. ↑ "Summary Basis of Decision - Rholistiq". Health Canada. 23 October 2014. Retrieved 6 August 2022.
  5. 1 2 3 4 "Rezurock- belumosudil tablet". DailyMed. Archived from the original on 21 August 2021. Retrieved 20 August 2021.
  6. 1 2 3 4 5 6 7 "FDA approves belumosudil for chronic graft-versus-host disease". U.S. Food and Drug Administration (FDA). 16 July 2021. Archived from the original on 16 July 2021. Retrieved 16 July 2021.PD-icon.svg This article incorporates text from this source, which is in the public domain.
  7. 1 2 Boerma M, Fu Q, Wang J, Loose DS, Bartolozzi A, Ellis JL, et al. (October 2008). "Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin". Blood Coagulation & Fibrinolysis. 19 (7): 709–18. doi:10.1097/MBC.0b013e32830b2891. PMC   2713681 . PMID   18832915.{{cite journal}}: CS1 maint: overridden setting (link)
  8. ↑ Park J, Chun KH (5 May 2020). "Identification of novel functions of the ROCK2-specific inhibitor KD025 by bioinformatics analysis". Gene. 737 144474. doi:10.1016/j.gene.2020.144474. PMID   32057928. S2CID   211111888.
  9. 1 2 3 4 5 "Drug Trials Snapshots: Rezurock". U.S. Food and Drug Administration. 16 July 2021. Archived from the original on 3 June 2023. Retrieved 25 June 2023.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  10. 1 2 Advancing Health Through Innovation: New Drug Therapy Approvals 2021. U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original (PDF) on 6 December 2022. Retrieved 22 January 2023.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  11. ↑ "KD025 - Clinical Trials". ClinicalTrials.gov. Archived from the original on 25 July 2020. Retrieved 25 July 2020.
  12. ↑ Flynn R, Paz K, Du J, Reichenbach DK, Taylor PA, Panoskaltsis-Mortari A, et al. (April 2016). "Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism". Blood. 127 (17): 2144–54. doi:10.1182/blood-2015-10-678706. PMC   4850869 . PMID   26983850.{{cite journal}}: CS1 maint: overridden setting (link)
  13. ↑ Shanley M (6 October 2017). "Therapy to Treat Transplant Complications Gets Orphan Drug Designation". RareDiseaseReport. Archived from the original on 14 February 2019. Retrieved 25 July 2018.{{cite web}}: CS1 maint: overridden setting (link)
  14. ↑ Clinical trial number NCT03640481 for "Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy" at ClinicalTrials.gov
  15. ↑ "Rezurock EPAR". European Medicines Agency (EMA). 17 October 2025. Retrieved 27 October 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.